Table 3

Achievement of European treatment targets at 12 months

Target*Polypill-based careUsual careRR† (95% CI)
n/N (crude %)Estimated† % (95% CI)n/N (crude %)Estimated† % (95% CI)
BP865/1393 (62)54 (44 to 67)776/1347 (58)50 (41 to 62)1.08 (1.02 to 1.15)‡
SBP919/1393 (66)60 (52 to 70)831/1347 (62)56 (48 to 66)1.07 (1.01 to 1.13)‡
DBP1183/1393 (85)80 (71 to 90)1092/1347 (81)75 (67 to 85)1.05 (1.02 to 1.09)‡
LDL524/1343 (39)43 (35 to 51)443/1294 (34)38 (31 to 46)1.13 (1.02 to 1.25)‡
Antiplatelet§1038/1086 (96)93 (88 to 98)1031/1078 (96)93 (89 to 98)1.00 (0.98 to 1.01)
BP and LDL and antiplatelet§331/1377 (24)24 (22 to 26)252/1336 (19)19 (17 to 21)1.27 (1.10 to 1.47)‡
  • *See table 1 for criteria.

  • †Estimated proportions and risk ratios were obtained from a log-binomial regression model as described in the methods section.

  • ‡P<0.05 after Holm-Bonferroni correction for multiple testing of targets within the same guideline.

  • §Antiplatelet target only applicable to people with established cardiovascular disease.

  • BP, blood pressure; DBP, diastolic blood pressure; LDL, low-density lipoprotein; RR, risk ratio; SBP, systolic blood pressure.